Summary & Overview
HCPCS Level II J2545: Pentamidine Inhalation Solution, 300 mg
HCPCS Level II code J2545 covers pentamidine isethionate inhalation solution (FDA-approved, non-compounded), packaged as a 300 mg unit dose for administration through durable medical equipment. This code matters nationally because it identifies a specific antimicrobial therapy delivered by inhalation for specialized respiratory indications, which affects coverage determinations, DME billing processes, and pharmacy-supplied unit-dose reimbursement.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for inhaled pentamidine, common settings of use (home or facility with DME support), and the administrative implications of coding a drug as an HCPCS Level II billed product.
The publication provides benchmarks and operational details relevant to claims processing and billing workflows, highlights payer coverage considerations, and outlines where to find policy updates that can affect prior authorization and payment. It also summarizes the service line implications for providers and DME suppliers, and notes gaps where input data was not available. This national-level summary is designed to support revenue cycle, clinical billing, and policy teams in understanding how J2545 is used in practice and what aspects typically drive payer queries and utilization management.
Billing Code Overview
HCPCS Level II code J2545 represents pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg. This code denotes a prescription inhalation antimicrobial supplied as a unit-dose formulation and intended for administration via durable medical equipment.
-
Service type: Drug administration via inhalation solution (unit dose)
-
Typical site of service: Durable medical equipment setting (home or facility-based use with DME support)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of advanced HIV infection presents for prophylaxis against Pneumocystis jirovecii pneumonia or for treatment of refractory or intolerant cases where inhaled pentamidine is indicated. The clinician prescribes J2545 (pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg). The patient arrives at an outpatient infusion clinic or pulmonary procedure suite where Durable Medical Equipment (DME) such as a nebulizer is available and set up by trained nursing staff. Vital signs and baseline oxygen saturation are recorded. The medication is drawn into the single-use unit-dose container and administered via the DME nebulizer over the recommended timeframe while the patient is monitored for bronchospasm, hypotension, or hypoglycemia. Post-administration observations include reassessment of respiratory status and documentation of lot number, dose, route, and the DME used. Billing uses J2545 for the drug per 300 mg unit; appropriate modifiers are appended as indicated by circumstance (for example, professional delivery, reduced services, or administrative reasons). Typical sites of service include outpatient infusion centers, pulmonary clinics, and hospital outpatient departments; home administration via DME with durable nebulizer setup may also occur when clinically appropriate and supported by the patient’s payer plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|